argenx SE 2019 IR
The report outlines argenx's transition into a late-stage clinical development company in 2019, preparing for its first product launch in 2021. Key achievements included completing enrollment for the Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis and initiating the Phase 3 ADVANCE trial in immune thrombocytopenia. The company also entered a major global collaboration with Janssen for cusatuzumab, receiving a $300 million upfront payment and a €176.7 million equity investment. Financially, argenx strengthened its position, ending the year with €1,335.8 million in cash, cash equivalents, and current financial assets.
Company: argenx SE
Sector: Manufacturing
Country: Netherlands
Year: 2019
Type: IR
Pages: 284
Back to company
argenx SE
Annual Report
The report outlines argenx's transition into a late-stage clinical development company in 2019, preparing for its first product launch in 2021. Key achievements included completing enrollment for the Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis and initiating the Phase 3 ADVANCE trial in immune thrombocytopenia. The company also entered a major global collaboration with Janssen for cusatuzumab, receiving a $300 million upfront payment and a €176.7 million equity investment. Financially, argenx strengthened its position, ending the year with €1,335.8 million in cash, cash equivalents, and current financial assets.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Published
Mar 31, 2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees